Next Generation Sequencing of Reactive Stroma and Residual Breast Cancer Cells in Tumor Bed after Neoadjuvant Chemotherapy

Next Generation Sequencing of Reactive Stroma and Residual Breast Cancer Cells in Tumor Bed after Neoadjuvant Chemotherapy

Primary systemic or neoadjuvant chemotherapy of breast cancer has become a standard therapy option in locally advanced or predefined intrinsic subtypes such as triple negative or Her2 positive breast cancer. Neoadjuvant chemotherapy can result in complete pathological response without residual tumor...

Full description

Bibliographic Details
Main Authors: Zsuzsanna Varga, Ailsa Christiansen, Magdalena Lukamowicz-Rajska, Aashil A. Batavia, Adriana von Teichman, Peter Schraml, Holger Moch
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Cancers
Subjects:
pathogenic driver mutations
chemotherapy
regressive tumor bed
breast cancer
Online Access:https://www.mdpi.com/2072-6694/14/22/5609

Internet

https://www.mdpi.com/2072-6694/14/22/5609

Similar Items